Genetron Holdings Limited (GTH) prices its IPO of 16.0M (from 13.0M) American Depositary Shares (ADSs), each representing five ordinary shares, at $16.00 per ADS.
Underwriters’ over-allotment is an additional 2.4M ADSs.
The Beijing-based company provides next-gen sequencing (NGS)-based molecular testing services in oncology.
Trading on the Nasdaq Global Market commences today.
2019 Financials: Revenue: $45.7M (+44%); Net Loss: ($95.5M) (-45%); Cash Consumption: ($27.8M) (+2%).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.